Minocycline: far beyond an antibiotic.
TLDR
A review will cover the most important topics in the pharmacology of minocycline to date, supporting its evaluation as a new therapeutic approach for many of the diseases described herein.Abstract:
Minocycline is a second-generation, semi-synthetic tetracycline that has been in therapeutic use for over 30 years because of its antibiotic properties against both gram-positive and gram-negative bacteria. It is mainly used in the treatment of acne vulgaris and some sexually transmitted diseases. Recently, it has been reported that tetracyclines can exert a variety of biological actions that are independent of their anti-microbial activity, including anti-inflammatory and anti-apoptotic activities, and inhibition of proteolysis, angiogenesis and tumour metastasis. These findings specifically concern to minocycline as it has recently been found to have multiple non-antibiotic biological effects that are beneficial in experimental models of various diseases with an inflammatory basis, including dermatitis, periodontitis, atherosclerosis and autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease. Of note, minocycline has also emerged as the most effective tetracycline derivative at providing neuroprotection. This effect has been confirmed in experimental models of ischaemia, traumatic brain injury and neuropathic pain, and of several neurodegenerative conditions including Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis and spinal cord injury. Moreover, other pre-clinical studies have shown its ability to inhibit malignant cell growth and activation and replication of human immunodeficiency virus, and to prevent bone resorption. Considering the above-mentioned findings, this review will cover the most important topics in the pharmacology of minocycline to date, supporting its evaluation as a new therapeutic approach for many of the diseases described herein.read more
Citations
More filters
Journal ArticleDOI
Gut Dysbiosis Is Linked to Hypertension
Tao Yang,Monica M Santisteban,Vermali Rodriguez,Eric Li,Niousha Ahmari,Jessica Marulanda Carvajal,Mojgan Zadeh,Minghao Gong,Yanfei Qi,Jasenka Zubcevic,Bikash Sahay,Carl J. Pepine,Mohan K. Raizada,Mansour Mohamadzadeh +13 more
TL;DR: It is demonstrated that high blood pressure is associated with gut microbiota dysbiosis, both in animal and human hypertension, and dietary intervention to correct gut microbiota could be an innovative nutritional therapeutic strategy for hypertension.
Journal ArticleDOI
Role of Inflammation in Diabetic Retinopathy
TL;DR: This review focuses on the involvement of inflammation in the pathophysiology of diabetic retinopathy with special emphasis on the functional relationships between glial cells and neurons, and summarizes recent advances using novel targets to inhibit inflammation.
Journal ArticleDOI
Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine
Yuichi Maeda,Takashi Kurakawa,Eiji Umemoto,Daisuke Motooka,Yoshinaga Ito,Kazuyoshi Gotoh,Keiji Hirota,Masato Matsushita,Yoki Furuta,Masashi Narazaki,Noriko Sakaguchi,Hisako Kayama,Shota Nakamura,Tetsuya Iida,Yukihiko Saeki,Atsushi Kumanogoh,Shimon Sakaguchi,Kiyoshi Takeda +17 more
TL;DR: The aim of this study was to investigate whether altered composition of human intestinal microbiota in RA patients contributes to the development of arthritis.
Journal ArticleDOI
Retinal microglia: Just bystander or target for therapy?
TL;DR: It is concluded that this resident immune cell of the retina cannot be simply regarded as bystander of disease but may instead be a potential therapeutic target to be modulated in the treatment of degenerative and inflammatory diseases ofThe retina.
Journal ArticleDOI
Traumatic Brain Injuries: Pathophysiology and Potential Therapeutic Targets.
TL;DR: An overview of the pathophysiology of TBI and the underlying molecular mechanisms is given, followed by an update on novel therapeutic targets and agents and recent development of various approaches of drug delivery to the CNS is discussed.
References
More filters
Journal ArticleDOI
Regulated Translation Initiation Controls Stress-Induced Gene Expression in Mammalian Cells
Heather P. Harding,Isabel Novoa,Yuhong Zhang,Huiqing Zeng,Ronald C. Wek,Matthieu Schapira,David Ron +6 more
TL;DR: Protein kinases that phosphorylate the alpha subunit of eukaryotic initiation factor 2 (eIF2alpha) are activated in stressed cells and negatively regulate protein synthesis, resulting in the induction of the downstream gene CHOP (GADD153).
Journal ArticleDOI
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor.
Seong-Woon Yu,Hongmin Wang,Marc F. Poitras,Carmen Coombs,William J. Bowers,Howard J. Federoff,Guy G. Poirier,Ted M. Dawson,Valina L. Dawson +8 more
TL;DR: It is shown that PARP-1 activation is required for translocation of apoptosis-inducing factor (AIF) from the mitochondria to the nucleus and that AIF is necessary for PARp-1–dependent cell death.
Journal ArticleDOI
Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease
Du Chu Wu,Vernice Jackson-Lewis,Miquel Vila,Kim Tieu,Peter Teismann,Caryn Vadseth,Dong-Kug Choi,Harry Ischiropoulos,Serge Przedborski +8 more
TL;DR: It is shown that minocycline, an approved tetracycline derivative that inhibits microglial activation independently of its antimicrobial properties, mitigates both the demise of nigrostriatal dopaminergic neurons and the formation of nitrotyrosine produced by MPTP.
Journal ArticleDOI
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
Sawsan Youssef,Olaf Stüve,Juan C. Patarroyo,Pedro J. Ruiz,Pedro J. Ruiz,Jennifer L. Radosevich,Eun Mi Hur,Manuel Bravo,Dennis J. Mitchell,Raymond A. Sobel,Lawrence Steinman,Scott S. Zamvil +11 more
TL;DR: It is shown that oral atorvastatin prevented or reversed chronic and relapsing paralysis and has pleiotropic immunomodulatory effects involving both APC and T-cell compartments.
Journal ArticleDOI
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice
Shan Zhu,Irina G. Stavrovskaya,Martin Drozda,Martin Drozda,Betty Y.S. Kim,Betty Y.S. Kim,Victor O. Ona,Victor O. Ona,Mingwei Li,Mingwei Li,Satinder Sarang,Allen S. Liu,Allen S. Liu,Dean M. Hartley,Du Chu Wu,Steven R. Gullans,Robert J. Ferrante,Robert J. Ferrante,Serge Przedborski,Serge Przedborski,Bruce S. Kristal,Robert M. Friedlander,Robert M. Friedlander +22 more
TL;DR: It is found that minocycline inhibits mitochondrial permeability-transition-mediated cytochrome c release, and this drug may be a novel therapy for ALS.